Heart failure & cardiomyopathiesCohort study
Long-Term Prognosis of Patients With Myocarditis Attributed to COVID-19 mRNA Vaccination, SARS-CoV-2 Infection, or Conventional Etiologies
- Retrospective cohort study
- nationwide (French National Health Data System)
- weighted Cox models
Authors' conclusion
Patients with post-COVID-19 mRNA vaccination myocarditis, contrary to those with post-COVID-19 myocarditis, show a lower frequency of cardiovascular complications than those with conventional myocarditis at 18 months.
Study context
- Population
- Individuals aged 12 to 49 years hospitalized for myocarditis in France, December 27, 2020 to June 30, 2022
- Participants
- 4,635 individuals
- Exposure
- Postvaccine or post-COVID-19 myocarditis vs conventional myocarditis
- Postvaccine myocarditisn = 558
- Post-COVID-19 myocarditisn = 298
- Conventional myocarditisn = 3,779reference
- Outcome
- Composite of:
- Hospital readmission for myopericarditis
- Other CV events
- All-cause death
- Follow-up
- 18 months following hospital admission
Main finding
As reported in the abstract
Composite clinical outcome · 18 months
Postvaccine myocarditis
32
events
Post-COVID-19 myocarditis
36
events
Conventional myocarditis
497
events
Each group vs conventional myocarditisWeighted hazard ratio (95% CI)
Postvaccine myocarditis
0.55(0.36–0.86)
Post-COVID-19 myocarditis
1.04(0.70–1.52)
Observational data: associations, not effects.
Further findings
Medical procedures and drug prescriptions after discharge · 18 months following hospital discharge
- Postvaccine and post-COVID-19 myocarditis followed a similar trend to conventional myocarditis
Original publication
Long-Term Prognosis of Patients With Myocarditis Attributed to COVID-19 mRNA Vaccination, SARS-CoV-2 Infection, or Conventional Etiologies. JAMA. Published 26 August 2024. doi:10.1001/jama.2024.16380
Summarised from the published abstract; every number is checked against it